Literature DB >> 17465246

Chromosomal aneusomy (chr 1, 11, 17) detected by fluorescence in situ hybridization may be a prognostic factor in breast cancer.

Masatsugu Takehisa1, Mitsunori Sasa, Yoshimi Bando, Toshiyuki Hirose, Tadaoki Morimoto, Taeko Nagao, Akira Tangoku.   

Abstract

The relationship between clinicopathological findings and the long-term prognosis was investigated in 42 breast cancer patients in whom aneusomy was detected for chromosomes 1, 11 and 17. The frequencies of aneusomy of those chromosomes were 78.6%, 47.5% and 52.5%, respectively, and more than 90% of anomalies consisted of polysomy. The relationship between aneusomy and the clinicopathological findings showed a statistical correlation with a high histological grade in the case of polysomy of chromosome 17 compared with disomy, indicating a tendency for a high incidence of lymph node metastasis. Analysis of the survival data revealed that the prognosis was poor when there was polysomy of chromosomes 1 or 11. These results indicate the possibility that aneusomy of chromosomes 1, 11 and 17 can serve as prognostic factors of poor outcome in breast cancer patients.

Entities:  

Mesh:

Year:  2007        PMID: 17465246

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification.

Authors:  Matteo Brunelli; Alessia Nottegar; Giuseppe Bogina; Anna Caliò; Luca Cima; Albino Eccher; Caterina Vicentini; Lisa Marcolini; Aldo Scarpa; Serena Pedron; Eleonora Brunello; Sakari Knuutila; Anna Sapino; Caterina Marchiò; Emilio Bria; Annamaria Molino; Luisa Carbognin; Giampaolo Tortora; Bharat Jasani; Keith Miller; Ibrahim Merdol; Lucia Zanatta; Licia Laurino; Tiina Wirtanen; Giuseppe Zamboni; Marcella Marconi; Marco Chilosi; Erminia Manfrin; Guido Martignoni; Franco Bonetti
Journal:  Am J Cancer Res       Date:  2015-06-15       Impact factor: 6.166

Review 2.  Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response.

Authors:  Monica M Reinholz; Amy K Bruzek; Daniel W Visscher; Wilma L Lingle; Matthew J Schroeder; Edith A Perez; Robert B Jenkins
Journal:  Lancet Oncol       Date:  2009-03       Impact factor: 41.316

3.  Clinicopathological Features of Breast Cancer with Polysomy 17 and Its Response to Neoadjuvant Chemotherapy.

Authors:  Hongxia Sun; Hui Chen; James Crespo; Guilin Tang; Melissa Robinson; Bora Lim; Ayşegül A Şahin
Journal:  Eur J Breast Health       Date:  2021-03-31

4.  HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients.

Authors:  Sasagu Kurozumi; Mary Padilla; Masafumi Kurosumi; Hiroshi Matsumoto; Kenichi Inoue; Jun Horiguchi; Izumi Takeyoshi; Tetsunari Oyama; Jim Ranger-Moore; D Craig Allred; Eslie Dennis; Hiroaki Nitta
Journal:  Breast Cancer Res Treat       Date:  2016-06-18       Impact factor: 4.872

5.  Genetic alterations associated with multiple primary malignancies.

Authors:  Jenny Nyqvist; Anikó Kovács; Zakaria Einbeigi; Per Karlsson; Eva Forssell-Aronsson; Khalil Helou; Toshima Z Parris
Journal:  Cancer Med       Date:  2021-05-31       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.